Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

BACKGROUND: Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs a...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yang, Zhang, Jianhua, Shen, Guofang, Liu, Lin, Zhao, Qingwei, Lu, Xiaoyang, Yang, Hongyu, Hong, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820915/
https://www.ncbi.nlm.nih.gov/pubmed/31665091
http://dx.doi.org/10.1186/s40360-019-0339-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820915/
https://www.ncbi.nlm.nih.gov/pubmed/31665091
http://dx.doi.org/10.1186/s40360-019-0339-1

Ejemplares similares